Overview
Valius Sciences provides precision oncology diagnostics that build detailed molecular profiles of tumors across DNA, RNA, and proteins to guide personalized cancer treatment. Its approach combines extensive multi-omic testing with a maximalist method that uses gene expression data and comparisons to thousands of other tumor samples to identify actionable targets often missed by standard tests, delivered through an AI-searchable, shareable platform. Unlike traditional static reports, Valius forms a partnership where patients and care teams continually access and analyze all data with the company’s scientific team for ongoing decision support. The goal is to empower patients and physicians with deep molecular insights to prioritize effective therapies and improve personalized cancer care.
Work here?Claim your company
Simplify's take
What believers are saying
- Valius raised $13.5 million on April 9, 2026, led by 8VC and Basis Set.
- October 2026 spatial RNA sequencing broadens target discovery beyond standard genomic panels.
- About 30% of cases uncovered actionable findings, supporting premium diagnostics demand.
What critics are saying
- Direct-pay pricing starts at $35,000, blocking reimbursement-driven scale before 2027.
- Only 10% of roughly 100 patients accessed therapy; commercialization remains weak.
- Competitors like Foundation Medicine and Tempus own physician workflows, squeezing Valius's adoption.
What makes Valius Sciences unique
- Valius combines DNA, RNA, protein, and spatial profiling across 25 cancer types.
- It sells partnerships, not PDFs, with patient-accessible raw data and query tools.
- Brian Schulte became CMO on October 13, 2026, strengthening clinical credibility.
Help us improve and share your feedback! Did you find this helpful?